HOME >> MEDICINE >> NEWS
JCI table of contents: January 19, 2006

of the fibronectin scaffold by pro-angiogenic astrocytes.

TITLE: Tlx acts as a pro-angiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes

AUTHOR CONTACT:
Akiyoshi Uemura
RIKEN Center for Developmental Biology, Kobe, Japan
Phone: 81-78-306-1924; Fax: 81-78-306-1895; E-mail: auemura@cdb.riken.jp

View the PDF of this article at: https://www.the-jci.org/article.php?id=25964

IMMUNOLOGY
TLR2 both triggers and tames the immune response

It is an established premise that invading pathogens release antigens that bind to Toll-like receptors (TLR ligands) on the surface of various cells of the immune system. This event stimulates specialized immune cells to release secreted proteins that activate other immune cells, such as T cells, to join the fight to destroy invading bacteria or fungi. The proliferation and activity of T cells is carefully controlled by a subset of cells known as regulatory T cells (Tregs). Treg depletion may allow an overzealous immune response to turn against the body's own tissues, resulting in autoimmune disorders such as arthritis and diabetes, while overactive Tregs can hinder the immune response against a foreign pathogen. In a study in mice appearing online on January 19 in advance of print publication in the February 2006 issue of the Journal of Clinical Investigation, Gosse Adema and colleagues at the Radboud University Nijmegen Medical Centre in The Netherlands, reveal that the type 2 TLR (TLR2) lies at the center of how Tregs know when to suppress and when not to suppress the immune response. The authors show that during infection of mice with the fungus Candida albicans, TLR2 ligands bind directly to TLR2 on Tregs and promote Treg proliferation. Interestingly, this binding also temporarily inhibits the suppressive activ
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
19-Jan-2006


Page: 1 2 3 4 5 6

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents January

(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The Jerry ... at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over ... raised more than $13.5 million for programs and services designed to support patients and ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the Massachusetts-based charity ... (FSHD), will be the beneficiary of a collection of fundraising events this fall. From ... of the FSH Society and further FSHD research. , The list of ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring Ed ... on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, qualification, ...
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... that, to date, more than 1,500 investor-families have received permanent green cards (I-829 ... EB-5 projects. , The I-829 petition is the final step of the EB-5 ...
Breaking Medicine News(10 mins):Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
(Date:9/1/2015)... , Sept. 1, 2015  Valeant Pharmaceuticals International, ... today announced that its affiliate has entered into ... was granted an exclusive license to develop and ... IL-17 receptor monoclonal antibody in development for patients ... the agreement, Valeant will hold the exclusive rights ...
(Date:8/31/2015)... Pepperl+Fuchs, a world leader in process ... leading provider of HART protocol devices. The move ... its integrated solutions offerings and strengthen its position ... are pleased to add the MACTek WirelessHART product ... Bolin , Pepperl+Fuchs, executive vice president of the ...
Breaking Medicine Technology:Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
Cached News: